Hutchmed Completes Saffron Trial Enrolment, Results Due 2026

Hutchmed China has completed enrolment for its phase 3 Saffron trial evaluating the combination of Orpathys and Tagrisso in lung cancer patients. The final patient was randomized on October 31, with topline results expected in the first half of 2026. The trial compares the Orpathys-Tagrisso combination with standard platinum-based doublet chemotherapy and aims to support global regulatory filings for approval. Lung cancer is the world's leading cause of cancer death, accounting for one-fifth of all cancer-related deaths.